### PATENT COOPERATION TREATY

# **PCT**

# Translation INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	<del></del>			
Applicant's or agent's file reference	FOR FURTHER ACTION	See Form PCT/IPEA/416		
P03-0030PCT				
International application No.	International filing date (day/month/yea			
PCT/JP2004/004190	25.03.2004	26.03.2003		
International Patent Classification (IPC) or	national classification and IPC			
Applicant PHARMADESIGN, INC.				
This report is the international p under Article 35 and transmitted	reliminary examination report, established to the applicant according to Article 36.	by this International Preliminary Examining Authority		
2. This REPORT consists of a total	of 6 sheets, i	including this cover sheet.		
3. This report is also accompanied by	by ANNEXES, comprising:			
a. (sent to the applicant	and to the International Bureau) a total of	4 sheets, as follows:		
sheets of the de	scription, claims and/or drawings which hav	e been amended and are the basis for this report and/or (see Rule 70.16 and Section 607 of the Administrative		
sheets which su		rity considers contain an amendment that goes beyond adicated in item 4 of Box No. I and the Supplemental		
•	onal Bureau only) a total of (indicate type and	d number of electronic carrier(s))		
		, containing a sequence listing and/or tables supplemental Box Relating to Sequence Listing (see		
4. This report contains indications i				
$\square$				
	f the report			
Box No. II Priority	,			
Box No. III Non-es	tablishment of opinion with regard to novelt	y, inventive step and industrial applicability		
Box No. IV Lack o	funity of invention			
	ed statement under Article 35(2) with regard as and explanations supporting such statement	to novelty, inventive step or industrial applicability;		
Box No. VI Certair	documents cited			
Box No. VII Certair	defects in the international application			
Box No. VIII Certair	observations on the international application	n		
Date of submission of the demand  Date of completion of this report				
Name and mailing address of the IPEA/JP	Authorized office	eer		
Facsimile No.	Telephone No			

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/004190

Box	No. I	Basis of the report				
1.	<ol> <li>With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.</li> </ol>					
		This report is based on translations from the original language which is the language of a translation furnished for the purportion.			·	
		international search (Rule 12.3 and 23.1(b))				
		publication of the international application (Rule 12.4)				
		international preliminary examination (Rule 55.2 and/o	•			
2.	recei	regard to the <b>elements</b> of the international application, this reviving Office in response to an invitation under Article 14 are report):				
		the international application as originally filed/furnished				
	$\boxtimes$	the description:				
		pages 1,2,5-23		<del></del>	as originally filed/furnished	
		pages* 3,3/1,4	received by this Authority on	26.01	. 2005	
		pages*	received by this Authority on			
	$\boxtimes$	the claims:				
		nos. 7-10			as originally filed/furnished	
		nos.*	as amended (togethe	r with an	y statement) under Article 19	
		nos.* 1-6	received by this Authority on	26.01	.2005	
		nos.*	received by this Authority on			
	$\boxtimes$	the drawings:				
		sheets 1/11-11/11			as originally filed/furnished	
		sheets*			-	
		sheets*				
	$\boxtimes$	a sequence listing and/or any related table(s) - see Supplem		isting.		
3.	$\overline{\Box}$	The amendments have resulted in the cancellation of:				
-		the description, pages				
		the claims, nos.				
		the sequence listing (specify):				
4.	_	any table(s) related to sequence listing (specify):  This report has been established as if (some of) the amend	Imante annoyed to this report and			
7.	Ш	they have been considered to go beyond the disclosure as fi	led, as indicated in the Suppleme	ntal Box	(Rule 70.2(c)).	
		the description, pages				
		the claims, nos.				
		the sequence listing (specify):				
*	If it	em 4 applies, some or all of those sheets may be marked "sup	perseded."			

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/004190

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1.	Statement			
	Novelty (N)	Claims	1-10	YES
		Claims		NO
	Inventive step (IS)	Claims	1-10	YES
		Claims		NO
	Industrial applicability (IA)	Claims	1-10	YES
		Claims		NO

#### 2. Citations and explanations (Rule 70.7)

- Document 1: The Journal of General Physiology, Vol. 115, No. 5, 2000, pages 583 to 598
- Document 2: WO 01/76618 A1 (Univ. New York State Res. Found.), 18 October 2001
- Document 3: Nature, Vol. 409, No. 6816, 2001, pages 35 to 36

The invention that is set forth in claims 1 to 10 is not disclosed in any of documents 1 to 3, which are cited in the international search report; therefore, the invention in question is novel and involves an inventive step.

International application No.
PCT/JP2004/004190

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

#### 1. Claim 3

The polypeptides (or salts thereof) that are set forth in claim 3 are characterized in that: they comprise an "amino acid sequence that is configured by deleting, substituting inserting or adding one or a plurality of amino acids" within the amino acid sequences that are represented by SEQ ID NO: 1 and SEQ ID NO: 2; they form intramolecular disulfide bonds; and they exhibit an activity whereby they inhibit mechano-sensitive channels.

Therein, the number of amino acids within the amino acid sequences that are represented by SEQ ID NO: 1 and SEQ ID NO: 2 are as follows: the amino acid sequence that is represented by SEQ ID NO: 1 comprises 10 amino acids, and the amino acid sequence that is represented by SEQ ID NO: 2 comprises 8 amino acids. Therefore, deleting amino acids at arbitrary positions, substituting amino acids at arbitrary positions with an arbitrary amino acid from among the approximately 20 types of existing amino acids, or inserting and/or adding (an) arbitrary amino acid(s) at arbitrary positions within these amino acid sequences will give a large number of amino acid sequences that have a structure which is capable of forming intramolecular disulfide bonds, regardless of whether or not these amino acid sequences exhibit an activity whereby they inhibit mechano-sensitive channels (ultimately, since it is sufficient that an intramolecular disulfide bond be formed, the Cys molecules within SEQ ID NO: 1 or 2 can be substituted freely as long as there are two Cys molecules at arbitrary positions so that in the end an intramolecular

International application No.
PCT/JP2004/004190

Box No. VIII Certain observations on the international application

disulfide bond will be formed).

Consequently, it is thought that a person skilled in the art would have to carry out a excessive amount of screening and experimentation in order to select the amino acid sequences that exhibit an activity whereby they inhibit mechano-sensitive channels from among this large number of amino acid sequences, even with consideration of common technical knowledge at the time the present application was filed.

As a result, the detailed description of the present invention cannot be considered to be disclosed in a manner that is sufficiently clear and complete for the invention that is set forth in claim 3 to be carried out by a person skilled in the art.

#### 2. Claims 9 and 10

The inventions set forth in claims 9 and 10 include inhibitors or therapeutic agents which comprise the polypeptides that are set forth in claim 3.

Consequently, due to the fact that the polypeptides that are set forth in claim 3 suffer from the defects that are indicated in section 1, above, the inventions set forth in claims 9 and 10, which include inhibitors or therapeutic agents that comprise the polypeptides that are set forth in claim 3, will also suffer from the same defects as are indicated above.

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/JP2004/004190

			_
Sup	plemo	ental Box Relating to Sequence Listing	10.75
Con	tinua	tion of Box No. I, item 2:	
1.	With	n regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention report was established on the basis of:	,
	a.	type of material	
		a sequence listing	
		table(s) related to the sequence listing	
	b.	format of material	
		in written format	
		in computer readable form	
	c.	time of filing/furnishing	
		contained in the international application as filed	
		filed together with the international application in computer readable form	
		furnished subsequently to this Authority for the purposes of search and/or examination	
		received by this Authority as an amendment* on	
		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or	
2.		furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	
3.	Ad	litional comments:	
1			
Ì			
,		em 4 in Box No. I applies, the listing and/or table(s) related thereto, which form part of the basis of the report, may be marked perseded "	